ArticleCancer communications (London, England)2025

Evaluation of exposure-response-safety relationship of model-informed low-dose 500 mg abiraterone acetate in prostate cancer patients.

Edmund Chiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.